Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year employment status in multiple sclerosis patients.

Kadrnozkova L, Vaneckova M, Sobisek L, Benova B, Kucerova K, Motyl J, Andelova M, Novotna K, Lizrova Preiningerova J, Krasensky J, Havrdova E, Horakova D, Uher T.

J Neurol Sci. 2018 May 15;388:87-93. doi: 10.1016/j.jns.2018.02.045. Epub 2018 Mar 6.

PMID:
29627038
2.

The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis.

Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M.

J Neuroimaging. 2018 May;28(3):328-337. doi: 10.1111/jon.12505. Epub 2018 Feb 27.

PMID:
29485230
3.

Cognitive clinico-radiological paradox in early stages of multiple sclerosis.

Uher T, Krasensky J, Sobisek L, Blahova Dusankova J, Seidl Z, Kubala Havrdova E, Sormani MP, Horakova D, Kalincik T, Vaneckova M.

Ann Clin Transl Neurol. 2017 Dec 15;5(1):81-91. doi: 10.1002/acn3.512. eCollection 2018 Jan.

4.

Pathological cut-offs of global and regional brain volume loss in multiple sclerosis.

Uher T, Vaneckova M, Krasensky J, Sobisek L, Tyblova M, Volna J, Seidl Z, Bergsland N, Dwyer MG, Zivadinov R, De Stefano N, Sormani MP, Havrdova EK, Horakova D.

Mult Scler. 2017 Nov 1:1352458517742739. doi: 10.1177/1352458517742739. [Epub ahead of print]

PMID:
29143562
5.

Towards personalized therapy for multiple sclerosis: prediction of individual treatment response.

Kalincik T, Manouchehrinia A, Sobisek L, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Girard M, Prat A, Duquette P, Grammond P, Sola P, Hupperts R, Grand'Maison F, Pucci E, Boz C, Alroughani R, Van Pesch V, Lechner-Scott J, Terzi M, Bergamaschi R, Iuliano G, Granella F, Spitaleri D, Shaygannejad V, Oreja-Guevara C, Slee M, Ampapa R, Verheul F, McCombe P, Olascoaga J, Amato MP, Vucic S, Hodgkinson S, Ramo-Tello C, Flechter S, Cristiano E, Rozsa C, Moore F, Luis Sanchez-Menoyo J, Laura Saladino M, Barnett M, Hillert J, Butzkueven H; MSBase Study Group.

Brain. 2017 Sep 1;140(9):2426-2443. doi: 10.1093/brain/awx185.

PMID:
29050389
6.

A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study.

Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R.

J Neuroimaging. 2017 Nov;27(6):620-629. doi: 10.1111/jon.12445. Epub 2017 May 2.

PMID:
28464417
7.

Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.

Burgetova A, Dusek P, Vaneckova M, Horakova D, Langkammer C, Krasensky J, Sobisek L, Matras P, Masek M, Seidl Z.

AJNR Am J Neuroradiol. 2017 Jun;38(6):1079-1086. doi: 10.3174/ajnr.A5166. Epub 2017 Apr 27.

8.

Serum lipid profile changes predict neurodegeneration in interferon-β1a-treated multiple sclerosis patients.

Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M.

J Lipid Res. 2017 Feb;58(2):403-411. doi: 10.1194/jlr.M072751. Epub 2016 Dec 6.

9.

Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach.

Uher T, Vaneckova M, Sormani MP, Krasensky J, Sobisek L, Dusankova JB, Seidl Z, Havrdova E, Kalincik T, Benedict RH, Horakova D.

Eur J Neurol. 2017 Feb;24(2):292-301. doi: 10.1111/ene.13200. Epub 2016 Nov 22.

PMID:
27873386
10.

Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5).

Novotna K, Sobisek L, Horakova D, Havrdova E, Lizrova Preiningerova J.

Eur Neurol. 2016;76(3-4):99-104. Epub 2016 Aug 6.

PMID:
27497974
11.

Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?

Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R, Horakova D.

Mult Scler. 2017 Feb;23(2):242-252. doi: 10.1177/1352458516650525. Epub 2016 Jul 11.

PMID:
27230790
12.

Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis.

Uher T, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Ramasamy D, Zivadinov R, Havrdova E, Kalincik T, Horakova D.

Mult Scler. 2017 Jan;23(1):51-61. doi: 10.1177/1352458516642314. Epub 2016 Jul 11.

PMID:
27053635

Supplemental Content

Loading ...
Support Center